RESEARCH

Upregulation of Apoptosis Related Genes in Clinically Normal Tongue Contralateral to Squamous Cell Carcinoma of the Oral Tongue, an Effort to Maintain Tissue Homeostasis

 N ima Attaran^{[1](http://orcid.org/0000-0002-6574-3628),2} · Philip J Coates³ · Katarina Zborayova² · Nicola Sgaramella^{1,4} · Karin Nylander¹ · Xiaolian Gu¹

Received: 2 August 2024 / Accepted: 27 August 2024 / Published online: 30 September 2024 © The Author(s) 2024

Abstract

Purpose The field cancerization concept indicates the presence of pre-cancerous changes in clinically normal tissue surrounding the tumor. In squamous cell carcinoma of the oral tongue (SCCOT) which is infrequently linked to human papillomavirus infection, we have previously reported that clinically normal tongue contralateral to tumor (NTCT) is molecularly abnormal. Here, combining our transcriptomic and genomic data, we aimed to investigate the contribution of molecular changes in NTCT to cancer development.

Methods Microarray gene expression data of 14 healthy controls, 23 NTCT and 29 SCCOT samples were investigated to characterize transcriptional profiles in NTCT. Whole exome sequencing and RNA-sequencing data of paired NTCT and tumor samples from 15 SCCOT patients were used to study correlation between copy number variation and differential gene expression.

Results Using supervised multivariate partial least squares discriminant analysis, a total of 61 mRNAs that distinguish NTCT from healthy tongue were selected. Functional enrichment analysis of the 22 upregulated genes showed increased "positive regulation of nitrogen compound metabolic process" in NTCT. All 12 genes involved in this process have roles in apoptosis (anti- and/or pro-apoptotic). Compared to healthy controls, Zinc Finger Protein 395 (*ZNF395*), a pro-apoptotic tumor suppressor located on chromosome 8p, was the only gene showing increased mRNA level in NTCT whereas decreased in SCCOT. Given the frequent loss of chromosome 8p in SCCOT, the impact of *ZNF395* copy number variation on gene expression was further examined, revealing a positive correlation between copy number and mRNA level (correlation coefficient=0.572, $p < 0.001$).

Conclusion NTCT is susceptible to malignant transformation, where tissue homeostasis is maintained at least partly through regulation of apoptosis. Loss of the pro-apoptotic gene *ZNF395* could thus initiate cancer development.

Keywords SCCOT · Field cancerization · Etiologic field effect · Apoptosis · *ZNF395*

 \boxtimes Xiaolian Gu

xiaolian.gu@umu.se

Nima Attaran nima.attaran@umu.se

Philip J Coates philip.coates@mou.cz

Katarina Zborayova katarina.zborayova@umu.se

Nicola Sgaramella sgaramellanicola12@gmail.com

Karin Nylander karin.nylander@umu.se

- ¹ Department of Medical Biosciences/Pathology, Umeå University, Building 6M, 2nd floor, Analysvägen 9, Umeå 90187, Sweden
- ² Department of Clinical Sciences, Umeå University, Umeå 90187, Sweden
- Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic
- ⁴ Department of Oral and Maxillo-Facial Surgery, Mater Dei Hospital, 70125 Bari, Italy

Introduction

Oral cancer accounted for approximately 2% of all new global cancer cases in 2022 [[1](#page-6-0)]. Approximately 90% of oral cancer are oral squamous cell carcinoma (OSCC) and associates with tobacco smoking, alcohol consumption, and betel nut chewing [[2](#page-6-1), [3\]](#page-6-2). The synergistic consumption of alcohol and tobacco increases the odds for OSCC occurrence [[4](#page-6-3)]. Unlike oropharyngeal cancer where human papillomavirus (HPV) infection is a recognized risk factor [[5](#page-6-4)], OSCC is infrequently associated with HPV infection [[6](#page-6-5)]. Patients with oral potentially malignant disorders (OPMDs), such as oral leukoplakia, oral erythroplakia, oral submucosal fibrosis and oral lichen planus, have an increased risk of malignant transformation compared to those with healthy mucosa [[3\]](#page-6-2). Squamous cell carcinoma of the oral tongue (SCCOT) arises from the squamous epithelium lining the anterior two-thirds of the tongue, which is the major anatomic subsite of OSCC [\[7](#page-6-6)]. The lack of anatomical barriers between the muscles in each half of the tongue and the presence of a rich lymphatic drainage and dense neural network make SCCOTs prone to loco-regional spread [\[8](#page-6-7)].

Genomic studies have shown that single nucleotide variations (SNVs) in *TP53*, *CDKN2A*, *TERT* promoter, *FAT1*, *NOTCH1* and *PIK3CA* are common somatic point mutations in SCCOT. Large structural mutations such as copy number variations (CNVs) in chromosomes 3, 5 and 8 are also frequent in SCCOT $[9-13]$ $[9-13]$ $[9-13]$ $[9-13]$. Notably, oncogenic mutations are found not only in tumors but also in non-tumor samples surrounding the tumor that appear clinically normal [[12](#page-6-10), [14,](#page-6-11) [15](#page-6-12)]. This can be explained by the "field cancerization" concept or the extended "etiologic field effect" model. The field cancerization concept was originally introduced by Slaughter et al. in 1953. It suggests that oral tumors are surrounded by clinically normal but genetically abnormal epithelial cells that contain one or more of the same oncogenic mutations as the tumor. This hypothesis was proposed to explain the high incidence of multiple second primary tumors and local recurrencies in these patients [[16\]](#page-6-13). Later studies have shown the field cancerization concept in other cancer types [[17\]](#page-6-14). The etiologic field effect model is an extension of this concept, highlighting that exposures to different factors cause widespread changes to cells in the organ, leading to altered cellular responses and promoting subse-quent cancer development [\[18](#page-6-15)]. Identification of mutations in normal cells that are not shared with the nearby tumor supports the etiologic field effect model [[12,](#page-6-10) [15\]](#page-6-12). Still, their contribution to cancer development remains ambiguous.

Transcriptome profiling of various tumor types has demonstrated aberrant gene expression in non-tumor cells in tumor-bearing patients compared to corresponding controls from healthy individuals [[19](#page-6-16)–[22\]](#page-6-17). By examining gene expression in non-tumor samples across eight tissues (bladder, breast, colon, liver, lung, prostate, thyroid and uterus) and corresponding tumor types, Aran et al. suggested a pancancer mechanism where pro-inflammatory signals from the tumor stimulate an inflammatory response in the surrounding tissue [[19](#page-6-16)]. Therefore, transcriptional alterations in nontumor could not be solely explained by the etiologic field effect model but also seemed to be influenced by the nearby tumor [[19](#page-6-16), [21\]](#page-6-18). As transcriptional data in non-tumor samples can provide prognostic information in multiple cancer types [[23–](#page-6-19)[26\]](#page-6-20), understanding the mechanism underlying the transcriptional changes in non-tumor cells is valuable in exploring the usage of non-tumor-based biomarkers.

Previously, we have reported altered transcriptional profiles in non-tumor tongue in patients with SCCOT compared to tongue tissue from healthy controls [[20](#page-6-21)]. Our non-tumor samples were taken contralaterally to SCCOT, at a distance of 3–5 cm from the tumor, hereafter referred to as NTCT (clinically Normal Tongue Contralateral to Tumor). Recently, we identified distinct genomic mutations and mutational signatures in NTCT compared to SCCOT [[12](#page-6-10)]. While we have provided evidence for etiologic field changes in NTCT, the question of which changes, if any, that are early events leading to malignancy remains unresolved. Delineating the transcriptional changes in NTCT and their association with genomic alterations could offer further insights into etiologic field changes, potentially aiding in the prediction of cancer development. In this study, combining our transcriptomic and genomic data, we sought to investigate how NTCT cells respond to the etiologic field effect and/or the separated tumor and to elucidate the contribution of molecular changes in NTCT to cancer development.

Materials and Methods

Samples and Data

This study is based on our previously published data [[26](#page-6-20)], comprising 14 healthy controls and 31 patients. The study has been approved by the Regional Ethics Review Board, Umeå, Sweden (Dnr 08-003 M and Dnr 2012-131-33 M) and performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all subjects. Incisional tumor biopsies and NTCT samples were taken at the same time during surgery. Healthy individuals provided biopsies from the lateral border of the tongue. Overall, a total of 14 healthy controls, 23 NTCT and 29 SCCOT samples were investigated, with paired NTCT and tumor samples available from 21 patients. Gene expression profiling was performed using Illumina HumanHT-12 v4 Expression BeadChip (Illumina Inc., San Diego, CA,

USA). Normalization of microarray data was performed using linear models and differential expression for microarray data (LIMMA) package [\[27](#page-6-22)]. Raw data was deposited in ArrayExpress (accession number E-MTAB-4678 and E-MTAB-5534). Clinical information is shown in Online Resource 1: Supplementary Table 1.

To confirm and extend findings generated from the microarray data, another dataset comprising whole exome sequencing (WES) and RNA-sequencing data of paired NTCT and tumor samples from 15 SCCOT patients [[12\]](#page-6-10) was also investigated. As reported previously, CNVs were identified using GATK copy number variant discovery tools [\[28](#page-6-23), [29\]](#page-6-24). Alignment, assembly, and quantification of RNA-sequencing data were performed using HISAT2 [\[30](#page-6-25)], StringTie [[31\]](#page-6-26), and RSEM (RNA-Seq by Expectation–Max-imization) [[32](#page-7-0)], respectively. Clinical information for these patients is shown in Online Resource 1: Supplementary Table 2.

Dimension Reduction Analysis

Unsupervised principal component analysis (PCA) (SIMCA 16, MKS Data Analytics Solutions, Umea, Sweden) was conducted to overview transcriptional profiles in healthy controls, NTCT and tumor samples. Supervised partial leastsquares–discriminant analysis (PLS–DA) was performed to identify discriminant factors between healthy control and NTCT, according to previously proposed guidelines [[33](#page-7-1)]. Genes with "variable influence of projection" ≥ 1 and "correlation coefficient between model and original data" > 0.9 were selected as the topmost discriminant factors.

Functional Enrichment Analysis

Functional enrichment analysis was performed for the topmost discriminant genes using g: Profiler [[34\]](#page-7-2), a tool that integrates gene sets from several databases, including Gene Ontology (GO), KEGG, Reactome (REAC) and WikiPathways (WP) to provide a comprehensive functional analysis of a given list of genes.

Differential Gene Expression Analysis

To determine the degree of differential expression between groups, fold change in mRNA levels and FDR were calculated using the ComparativeMarkerSelection tool in GenePattern [[35](#page-7-3)]. Comparisons were performed between NTCT and healthy control, NTCT and tumor, and between tumor and healthy control.

Statistical Analysis

Nonparametric Spearman correlation analysis was performed to evaluate correlation between mRNA levels and CNV using IBM SPSS Statistics 25 (IBM Corp., Armonk, NY, USA). A two-sided *p*-value <0.05 was considered significant. Statistical methods employed are performed by an experienced person with authorship on the manuscript (XG).

Results

Discriminating NTCT from Healthy Controls

PCA showed that the transcriptional profiles of NTCT were distinct from those of tumor samples, and broadly similar to healthy controls (Fig. [1](#page-3-0)a), as would be expected. Applying PLS-DA to identify discriminant factors between NTCT and healthy controls, 61 genes were identified as the topmost discriminant factors, with 39 mRNAs downregulated and 22 mRNAs upregulated in NTCT compared to healthy controls (Fig. [1](#page-3-0)b). These 61 genes and their degree of differential expression between different groups of samples (log fold change and FDR) are provided in Online Resource 1: Supplementary Table 3.

Discriminating Functional Changes in NTCT

Functional enrichment analysis of the 39 downregulated genes using g: Profiler showed that Cellular Component (CC) ontology of "cytoplasm" was the only enriched term found. For the 22 upregulated genes, several enriched terms in Biological Process (BP) and CC ontology were identified. The most significantly enriched biological process was "positive regulation of nitrogen compound metabolic process" (adjusted *p*-value=0.012, Table [1](#page-3-1)). Twelve genes contributed to this enrichment: nuclear factor I C (*NFIC*); BCL2 associated X, apoptosis regulator (*BAX*); SIN3 transcription regulator family member A (*SIN3A*); sortilin related receptor 1 (*SORL1*); aph-1 homolog A, gamma-secretase subunit (*APH1A*); MSL complex subunit 3 (*MSL3*); poly(rC) binding protein 2 (*PCBP2*); zinc finger protein 395 (*ZNF395*); endoplasmic reticulum protein 29 (*ERP29*); mediator complex subunit 12 (*MED12*); RANBP2-type and C3HC4-type zinc finger containing 1 (*RBCK1*); and bromodomain adjacent to zinc finger domain 1B (*BAZ1B*).

Patterns of mRNA Changes

Three patterns of changes were found comparing the twelve metabolism-regulatory mRNAs between healthy control,

Fig. 1 Discrimination of clinically normal tongue tissue contralateral to tumor (NTCT) from healthy tongue. (**a**) Principal component analysis plot (two components, R2X $[1] = 0.108$ $[1] = 0.108$ $[1] = 0.108$, R2X $[2] = 0.0883$ $[2] = 0.0883$ $[2] = 0.0883$) visualizing gene expression profiles in three groups of samples. (**b**) Volcano

plot showing selection of the highest-ranking genes that discriminate NTCT from healthy controls according to the partial least-squares– discriminant analysis model. VIP=variable influence of projection, p(corr)=correlation coefficient between model and original data

Table 1 Significantly enriched terms in Gene ontology: biological process (date of inquiry: 2024-01-22)

Term name	Term ID	Adjusted	Term	Inter-	Intersections
		p -value	size	sec-	
				tion	
				size	
Positive regulation of nitrogen compound	GO:0051173	0.012	3071	12	NFIC, BAX, SIN3A, SORL1, APH1A, MSL3,
metabolic process					PCBP2, ZNF395, ERP29, MED12, RBCK1, BAZ1B
Negative regulation of binding	GO:0051100	0.027	158	4	BAX, TLE5, SIN3A, SORL1
Regulation of nitrogen compound metabolic	GO:0051171	0.037	5587	15	ACIN1, NFIC, BAX, TLE5, SIN3A, SORL1,
process					APH1A, MSL3, CBY1, PCBP2, ZNF395, ERP29,
					MED12, RBCK1, BAZ1B
Positive regulation of macromolecule meta-	GO:0010604	0.046	3483	12	NFIC, BAX, SIN3A, SORL1, APH1A, MSL3,
bolic process					PCBP2, ZNF395, ERP29, MED12, RBCK1, BAZ1B

NTCT and tumor: (1) Upregulated in NTCT and tumor; (2) Upregulated only in NTCT (*MED12*); (3) Upregulated in NTCT but downregulated in tumor (*ZNF395*) (Fig. [2](#page-4-1)). Because NTCT showed an average upregulation and tumor samples an average downregulation of *ZNF395* mRNA compared to healthy controls, we investigated *ZNF395* levels in each of the 21 paired tumor and NTCT samples. A decrease from NTCT to tumor was demonstrated in all patients (Fig. [3](#page-4-0)a).

Expression of ZNF395 Correlates with CNV

The *ZNF395* gene is located on chromosome 8p. Our previous genomic study of 15 patients with SCCOT identified gain of chromosome 8 in NTCT and loss in tumor [[12\]](#page-6-10), a pattern similar to the transcriptional changes seen here. The correlation between *ZNF395* copy number and mRNA level was therefore analyzed using the dataset of the above-mentioned study, comprising both RNA sequencing data and copy number variation data of NTCT and tumor samples from 15 patients with SCCOT [[12\]](#page-6-10). According to RNA sequencing, all tumor samples except one (a human papillomavirus (HPV)-positive tumor) showed lower *ZNF395* mRNA levels than the matched NTCT (Fig. [3b](#page-4-0)). In addition, Spearman correlation analysis indicated a positive correlation between CNV and mRNA level (correlation coefficient=0.572, $p < 0.001$, Fig. [3c](#page-4-0)).

Discussion

Using a larger microarray dataset, we confirmed our previous finding that gene expression is altered in clinically normal tongue contralateral to SCCOT. More importantly, by investigating the highest-ranking genes that discriminate NTCT from healthy controls, we explored the cellular behaviors that distinguish NTCT from healthy tissues and tried to elucidate the underlying causes regarding etiological field effects and their impact on tumor development.

Nitrogen acquisition and utilization is essential for cell growth and proliferation [[36](#page-7-4)]. We found the "positive regulation of nitrogen compound metabolism" to be most active

Fig. 2 Box-plots showing mRNA levels of apoptosis related genes in healthy controls (H), clinically normal tongue tissue contralateral to tumor (NTCT) and tumor (T). Significance of differential expression

between two groups of samples are indicated: *False discovery rate $(FDR) < 0.05$, ** $FDR < 0.01$

Fig. 3 mRNA level and copy number of *ZNF395* in clinically normal tongue tissue contralateral to tumor (NTCT) and tumor samples. (**a**) Box-plot showing *ZNF395* mRNA levels quantified by microarray analysis in 21 paired samples. (**b**) Box-plot showing *ZNF395* mRNA levels quantified by RNA sequencing in 15 paired samples. Lines con-

necting data points indicate paired samples from the same patient. The red dot represents the human papillomavirus (HPV)-positive sample. (**c**) Scatter-plot showing correlations between mRNA level and gene copy number in 15 paired samples

in non-tumor samples. Notably, despite the terminology of this process, all 12 genes annotated within this biological process that we identified have roles related to apoptosis, with five being pro-apoptotic (*NFIC*, *BAX*, *MSL3*, *ZNF395* and *BAZ1B* [\[37](#page-7-7)[–41](#page-7-8)]), five anti-apoptotic (*SORL1*, *APH1A*, *PCBP2*, *MED12*, *RBCK1* [[42–](#page-7-9)[46](#page-7-10)]), and two either anti- or pro-apoptotic under different circumstances (*SIN3A* and *ERP29* [[47](#page-7-11)–[49\]](#page-7-12)). This is consistent with our previous finding of several apoptosis regulatory genes being upregulated in non-tumor samples compared to samples from healthy controls [\[20](#page-6-21)].

The etiologic field effect theory suggests that factors in the tissue environment and their interactions create a field that is susceptible to malignant transformation $[18]$ $[18]$. Compatible with this model, non-tumor samples from SCCOT patients commonly harbor SNVs and CNVs, but these are not shared with the patient's tumor, indicating that the tumor did not arise from a larger field of pre-neoplastic cells containing these genetic alterations [[12\]](#page-6-10). Using a mouse model, Colom et al. showed that multiple mutant clones in normal epithelium have an anti-tumorigenic role through cell competition, thereby preserving tissue integrity [[50](#page-7-5)]. Toyoshima-Sasatani et al. found that under DNA damage conditions, both mutation and apoptosis were induced in *Drosophila*, the balance and coordination between the two being important for tissue maintenance [[51](#page-7-6)]. Investigation of human tissues revealed that somatic mutations accumulate in normal tissues with aging and exposure to carcinogens. Clonal competition,

which involves apoptosis-mediated elimination of less fit cells, is an essential mechanism in directing the fate of normal tissues [[52](#page-7-13)]. Our finding that both pro-apoptotic and anti-apoptotic genes were upregulated in non-tumor tissues from patients with SCCOT might thus reflect ongoing cellular competition in response to etiologic field effect.

One of the apoptosis-related genes identified in this study is *ZNF395* (also known as papilloma virus binding factor (PBF)), located on chromosome 8p and encoding a transcription factor with a tumor suppressive role in several cancers [[53](#page-7-14)]. Besides its pro-apoptotic function [[40](#page-7-15)], it is also involved in the innate immune response [[54](#page-7-16)], cell growth [[53](#page-7-14)], migration and invasion [[55\]](#page-7-17). In pancreatic cancer, downregulation of *ZNF395* caused by loss of chromosome 8p is a critical step in driving progression of intraepithelial neoplasia into invasive carcinoma [[53\]](#page-7-14). Here, our genomic and transcriptomic data showed that an increase in *ZNF395* mRNA occurs in non-tumor samples but is decreased in HPV-negative SCCOT samples in association with gene loss. As loss of chromosome 8p is seen in most human epithelial cancers and confers tumor growth under stress conditions [[56\]](#page-7-18), our data imply that increased expression of *ZNF395* in non-tumor tissues plays a role in maintaining the tumor-free status of the tongue, until 8p loss occurs during the carcinogenic process.

HPV infection is not an established risk factor for OSCC. A recent meta-analysis revealed that the overall prevalence of HPV-positive OSCC is 6% [[6\]](#page-6-5). In our study, one tumor sample was HPV-positive. The distinct expression patten of *ZNF395* in the HPV-positive tumor indicates the difference in pathogenesis between HPV-negative and HPV-positive tumors. Given that *ZNF395* is involved in transcription of HPV genes [\[57](#page-7-19), [58](#page-7-20)], investigations of its role in HPV-positive tumors are warranted.

Comparing gene expression profiles in healthy tissue from cancer-free patients, non-tumor tissues and tumor cells from colon cancer patients, Sanz-Pamplona et al. showed that genes involved in extracellular matrix remodeling are activated in non-tumor samples, which might be due to crosstalk between proteins secreted by the tumor and receptors activated in the non-tumor samples [[21](#page-6-18)]. No alteration in genes involved in extracellular matrix remodeling was seen in our samples, although, due to the unique anatomical structure of the tongue, distinct crosstalk might exist also in tongue tissue. As gain of chromosome 8 and upregulation of *ZNF395* is a specific alteration in non-tumor tongue cells of SCCOT patients, we speculate that the prominent changes seen are caused by an etiologic field effect. In a field with multiple microenvironmental changes resulting from continued exposure to potentially carcinogenic agents, a tumor could be initiated when cells gain fitness advantage

 \bigcirc Springer

for uncontrolled cell proliferation and invasion, such as loss of *ZNF395*.

In summary, by applying multivariate discriminant analysis to investigate the transcriptional features of NTCT compared to healthy tongue samples from non-tumor-bearing volunteers, we have identified altered regulation of apoptosis-related genes in clinically normal tongue contralateral to SCCOT. The upregulation of both anti- and pro-apoptotic genes could represent ongoing cellular competition, a process that could determine whether a tumor develops or not. To provide comprehensive insight into the etiologic field effect, future studies should comprise more samples and ideally also multiple samples collected around the tumor. In addition, samples from patients with other oral malignancies and OPMDs should be included for comparison with SCCOT. Unveiling the hidden battlefield in NTCT could enhance our understanding of the mechanisms driving cancer development and contribute to improving early diagnosis and treatment.

Supplementary Information The online version contains supplementary material available at [https://doi.org/10.1007/s12105-](https://doi.org/10.1007/s12105-024-01695-6) [024-01695-6](https://doi.org/10.1007/s12105-024-01695-6).

Author Contributions N.A. and X.G. analysed data, P.J.C., K.Z., N.S., K.N. and X.G. interpreted data, N.A., P.J.C., K.N. and X.G. wrote the main manuscript text, K.N. and X.G. supervised the project. All authors reviewed the manuscript.

Funding This study was funded by Lion's Cancer Research Foundation, Umeå University; The Swedish Cancer Society (contract number 23 2775 Pj 01 H); Umeå University; Region Västerbotten; Ministry of Health Czech Republic, conceptual development of research organization (MMCI, 00209805). The funding sources had no role other than financial support.

Open access funding provided by Umea University.

Data Availability Microarray raw data was deposited in ArrayExpress with accession number E-MTAB-4678 and E-MTAB-5534. Processed RNA sequencing data and genomic copy number variation data are provided at the following link: https://umeauniversity-my.sharepoint. com/:f:/g/personal/xinguu04_ad_umu_se/EiacyiBdjiRKtaqvRo-8ohEBXYkTr2U56IeCZHb1FHpuiw? e=9jKzUV.

Declarations

Ethical Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent to Participate Informed consent was obtained from all individual participants included in the study.

Consent for Publication For this type of study consent for publication is not required.

Competing Interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.](http://creativecommons.org/licenses/by/4.0/) [org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

References

- 1. Global Cancer Observatory [cited 2024 February 13]; [https://gco.](https://gco.iarc.fr/en) [iarc.fr/en](https://gco.iarc.fr/en)
- 2. Chow LQM (2020) Head and Neck Cancer. N Engl J Med 382(1):60–72. <https://doi.org/10.1056/NEJMra1715715>
- 3. Tan Y, Wang Z, Xu M et al (2023) Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci 15(1):44. <https://doi.org/10.1038/s41368-023-00249-w>
- 4. Mello FW, Melo G, Pasetto JJ, Silva CAB, Warnakulasuriya S, Rivero ERC (2019) The synergistic effect of tobacco and alcohol consumption on oral squamous cell carcinoma: a systematic review and meta-analysis. Clin Oral Investig 23(7):2849–2859. <https://doi.org/10.1007/s00784-019-02958-1>
- 5. Lechner M, Liu J, Masterson L, Fenton TR (2022) HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 19(5):306–327. [https://](https://doi.org/10.1038/s41571-022-00603-7) doi.org/10.1038/s41571-022-00603-7
- 6. Katirachi SK, Gronlund MP, Jakobsen KK, Gronhoj C, von Buchwald C (2023) The prevalence of HPV in oral cavity squamous cell carcinoma. Viruses 15(2). <https://doi.org/10.3390/v15020451>
- 7. Matsuo K, Akiba J, Kusukawa J, Yano H (2022) Squamous cell carcinoma of the tongue: subtypes and morphological features affecting prognosis. Am J Physiol Cell Physiol 323(6):C1611– C23. <https://doi.org/10.1152/ajpcell.00098.2022>
- 8. Shetty SS, Kudpaje A, Jayaraj R, Rao V, Shah PK (2019) Tongue cancer: a discrete oral cavity subsite. Oral Oncol 99:104348. <https://doi.org/10.1016/j.oraloncology.2019.06.029>
- 9. Pickering CR, Zhang J, Neskey DM et al (2014) Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. Clin Cancer Res 20(14):3842–3848. [https://doi.org/10.1158/1078-0432.](https://doi.org/10.1158/1078-0432.CCR-14-0565) [CCR-14-0565](https://doi.org/10.1158/1078-0432.CCR-14-0565)
- 10. Vettore AL, Ramnarayanan K, Poore G et al (2015) Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance. Genome Med 7(1):98.<https://doi.org/10.1186/s13073-015-0219-2>
- 11. Gu X, Coates PJ, Boldrup L et al (2019) Copy number variation: a prognostic marker for young patients with squamous cell carcinoma of the oral tongue. J Oral Pathol Med 48(1):24–30. [https://](https://doi.org/10.1111/jop.12792) doi.org/10.1111/jop.12792
- 12. Gu X, Wang L, Coates PJ et al (2023) Evidence for etiologic field changes in tongue distant from tumor in patients with squamous cell carcinoma of the oral tongue. J Pathol 259(1):93–102. [https://](https://doi.org/10.1002/path.6025) doi.org/10.1002/path.6025
- 13. Arantes L, Cruvinel-Carloni A, de Carvalho AC et al (2020) TERT promoter mutation C228T increases risk for Tumor recurrence and death in Head and Neck Cancer patients. Front Oncol 10:1275.<https://doi.org/10.3389/fonc.2020.01275>
- 14. Jakubek YA, Chang K, Sivakumar S et al (2020) Large-scale analysis of acquired chromosomal alterations in non-tumor samples from patients with cancer. Nat Biotechnol 38(1):90–96. <https://doi.org/10.1038/s41587-019-0297-6>
- 15. Wu P, Xie C, Yang L et al (2021) The genomic architectures of tumour-adjacent tissues, plasma and saliva reveal evolutionary underpinnings of relapse in head and neck squamous cell carcinoma. Br J Cancer 125(6):854–864. [https://doi.org/10.1038/](https://doi.org/10.1038/s41416-021-01464-0) [s41416-021-01464-0](https://doi.org/10.1038/s41416-021-01464-0)
- 16. Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6(5):963–968
- 17. Curtius K, Wright NA, Graham TA (2018) An evolutionary perspective on field cancerization. Nat Rev Cancer 18(1):19–32. <https://doi.org/10.1038/nrc.2017.102>
- 18. Lochhead P, Chan AT, Nishihara R et al (2015) Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol 28(1):14–29. [https://doi.](https://doi.org/10.1038/modpathol.2014.81) [org/10.1038/modpathol.2014.81](https://doi.org/10.1038/modpathol.2014.81)
- 19. Aran D, Camarda R, Odegaard J et al (2017) Comprehensive analysis of normal adjacent to tumor transcriptomes. Nat Commun 8(1):1077.<https://doi.org/10.1038/s41467-017-01027-z>
- 20. Boldrup L, Gu X, Coates PJ et al (2017) Gene expression changes in tumor free tongue tissue adjacent to tongue squamous cell carcinoma. Oncotarget 8(12):19389–19402. [https://doi.org/10.18632/](https://doi.org/10.18632/oncotarget.14288) [oncotarget.14288](https://doi.org/10.18632/oncotarget.14288)
- 21. Sanz-Pamplona R, Berenguer A, Cordero D et al (2014) Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. Mol Cancer 13:46. [https://doi.](https://doi.org/10.1186/1476-4598-13-46) [org/10.1186/1476-4598-13-46](https://doi.org/10.1186/1476-4598-13-46)
- 22. Risk MC, Knudsen BS, Coleman I et al (2010) Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res 16(22):5414–5423. [https://doi.org/10.1158/1078-](https://doi.org/10.1158/1078-0432.CCR-10-0272) [0432.CCR-10-0272](https://doi.org/10.1158/1078-0432.CCR-10-0272)
- 23. Huang X, Stern DF, Zhao H (2016) Transcriptional profiles from paired normal samples offer complementary information on Cancer patient survival–evidence from TCGA Pan-cancer Data. Sci Rep 6:20567.<https://doi.org/10.1038/srep20567>
- 24. Oh E, Lee H (2023) Transcriptomic data in tumor-adjacent normal tissues harbor prognostic information on multiple cancer types. Cancer Med 12(10):11960–11970. [https://doi.org/10.1002/](https://doi.org/10.1002/cam4.5864) [cam4.5864](https://doi.org/10.1002/cam4.5864)
- 25. Attaran N, Gu X, Coates PJ et al (2020) Downregulation of TAP1 in Tumor-Free Tongue Contralateral to squamous cell carcinoma of the oral Tongue, an Indicator of Better Survival. Int J Mol Sci 21(17).<https://doi.org/10.3390/ijms21176220>
- 26. Gu X, Boldrup L, Coates PJ et al (2019) High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue. J Pathol Clin Res 5(4):240–247.<https://doi.org/10.1002/cjp2.138>
- 27. Shi W, Oshlack A, Smyth GK (2010) Optimizing the noise versus bias trade-off for Illumina whole genome expression BeadChips. Nucleic Acids Res 38(22):e204. [https://doi.org/10.1093/nar/](https://doi.org/10.1093/nar/gkq871) [gkq871](https://doi.org/10.1093/nar/gkq871)
- 28. Van der Auwera GA (2020) OCB, *Genomics in the Cloud: Using Docker, GATK, and WDL in Terra (1st Edition)*. : O'Reilly Media
- 29. McKenna A, Hanna M, Banks E et al (2010) The genome analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20(9):1297–1303. [https://](https://doi.org/10.1101/gr.107524.110) doi.org/10.1101/gr.107524.110
- 30. Kim D, Langmead B, Salzberg SL (2015) HISAT: a fast spliced aligner with low memory requirements. Nat Methods 12(4):357– 360.<https://doi.org/10.1038/nmeth.3317>
- 31. Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL (2015) StringTie enables improved reconstruction of

a transcriptome from RNA-seq reads. Nat Biotechnol 33(3):290– 295.<https://doi.org/10.1038/nbt.3122>

- 32. Li B, Dewey CN (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12:323. <https://doi.org/10.1186/1471-2105-12-323>
- 33. Wheelock AM, Wheelock CE (2013) Trials and tribulations of 'omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol Biosyst 9(11):2589–2596. <https://doi.org/10.1039/c3mb70194h>
- 34. Kolberg L, Raudvere U, Kuzmin I, Adler P, Vilo J, Peterson H (2023) G:profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res 51(W1):W207–W12. [https://doi.org/10.1093/nar/](https://doi.org/10.1093/nar/gkad347) [gkad347](https://doi.org/10.1093/nar/gkad347)
- 35. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP (2006) GenePattern 2.0. Nat Genet 38(5):500–501. [https://doi.](https://doi.org/10.1038/ng0506-500) [org/10.1038/ng0506-500](https://doi.org/10.1038/ng0506-500)
- 36. Kurmi K, Haigis MC (2020) Nitrogen Metabolism in Cancer and Immunity. Trends Cell Biol 30(5):408–424. [https://doi.](https://doi.org/10.1016/j.tcb.2020.02.005) [org/10.1016/j.tcb.2020.02.005](https://doi.org/10.1016/j.tcb.2020.02.005)
- 37. Zhang H, Luo Z, Tang J et al (2022) Transcription factor NFIC functions as a tumor suppressor in lung squamous cell carcinoma progression by modulating lncRNA CASC2. Cell Cycle 21(1):63–73.<https://doi.org/10.1080/15384101.2021.1995130>
- 38. Lopez A, Reyna DE, Gitego N et al (2022) Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer. Nat Commun 13(1):1199. [https://doi.org/10.1038/](https://doi.org/10.1038/s41467-022-28741-7) [s41467-022-28741-7](https://doi.org/10.1038/s41467-022-28741-7)
- 39. Kunisky AK, Anyaeche VI, Herron RS, Park CY, Hwang HW (2021) Shift in MSL1 alternative polyadenylation in response to DNA damage protects cancer cells from chemotherapeutic agent-induced apoptosis. Cell Rep 37(2):109815. [https://doi.](https://doi.org/10.1016/j.celrep.2021.109815) [org/10.1016/j.celrep.2021.109815](https://doi.org/10.1016/j.celrep.2021.109815)
- 40. Tsukahara T, Kimura S, Ichimiya S et al (2009) Scythe/BAT3 regulates apoptotic cell death induced by papillomavirus binding factor in human osteosarcoma. Cancer Sci 100(1):47–53. [https://](https://doi.org/10.1111/j.1349-7006.2008.00991.x) doi.org/10.1111/j.1349-7006.2008.00991.x
- 41. Cook PJ, Ju BG, Telese F, Wang X, Glass CK, Rosenfeld MG (2009) Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 458(7238):591–596. [https://](https://doi.org/10.1038/nature07849) doi.org/10.1038/nature07849
- 42. Zheng Z, Li X, Yang B et al (2023) SORL1 stabilizes ABCB1 to promote cisplatin resistance in ovarian cancer. Funct Integr Genomics 23(2):147.<https://doi.org/10.1007/s10142-023-01075-3>
- 43. Dunys J, Kawarai T, Sevalle J et al (2007) p53-Dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the gamma-secretase complex but is independent of its activity. J Biol Chem 282(14):10516–10525. [https://doi.org/10.1074/jbc.](https://doi.org/10.1074/jbc.M611572200) [M611572200](https://doi.org/10.1074/jbc.M611572200)
- 44. Ishii T, Igawa T, Hayakawa H, Fujita T, Sekiguchi M, Nakabeppu Y (2020) PCBP1 and PCBP2 both bind heavily oxidized RNA but cause opposing outcomes, suppressing or increasing apoptosis under oxidative conditions. J Biol Chem 295(34):12247–12261. <https://doi.org/10.1074/jbc.RA119.011870>
- 45. Srivastava S, Makala H, Sharma V, Suri V, Sarkar C, Kulshreshtha R (2022) MED12 is overexpressed in glioblastoma patients and serves as an oncogene by targeting the VDR/BCL6/

p53 axis. Cell Mol Life Sci 79(2):104. [https://doi.org/10.1007/](https://doi.org/10.1007/s00018-021-04056-6) [s00018-021-04056-6](https://doi.org/10.1007/s00018-021-04056-6)

- 46. Wang G, Zhuang Z, Shen S et al (2022) Regulation of PTEN and ovarian cancer progression by an E3 ubiquitin ligase RBCK1. Hum Cell 35(3):896–908. [https://doi.org/10.1007/](https://doi.org/10.1007/s13577-022-00681-w) [s13577-022-00681-w](https://doi.org/10.1007/s13577-022-00681-w)
- 47. Gambi G, Di Simone E, Basso V et al (2019) The Transcriptional Regulator Sin3A contributes to the oncogenic potential of STAT3. Cancer Res 79(12):3076–3087. [https://doi.org/10.1158/0008-](https://doi.org/10.1158/0008-5472.CAN-18-0359) [5472.CAN-18-0359](https://doi.org/10.1158/0008-5472.CAN-18-0359)
- 48. Shang C, Hong Y, Guo Y, Liu YH, Xue YX (2014) MiR-210 upregulation inhibits proliferation and induces apoptosis in glioma cells by targeting SIN3A. Med Sci Monit 20:2571–2577. [https://](https://doi.org/10.12659/MSM.892994) doi.org/10.12659/MSM.892994
- 49. Chen S, Zhang D (2015) Friend or foe: endoplasmic reticulum protein 29 (ERp29) in epithelial cancer. FEBS Open Bio 5:91–98. <https://doi.org/10.1016/j.fob.2015.01.004>
- 50. Colom B, Herms A, Hall MWJ et al (2021) Mutant clones in normal epithelium outcompete and eliminate emerging tumours. Nature 598(7881):510–514. [https://doi.org/10.1038/](https://doi.org/10.1038/s41586-021-03965-7) [s41586-021-03965-7](https://doi.org/10.1038/s41586-021-03965-7)
- 51. Toyoshima-Sasatani M, Imura F, Hamatake Y, Fukunaga A, Negishi T (2023) Mutation and apoptosis are well-coordinated for protecting against DNA damage-inducing toxicity in Drosophila. Genes Environ 45(1):11. [https://doi.org/10.1186/](https://doi.org/10.1186/s41021-023-00267-4) [s41021-023-00267-4](https://doi.org/10.1186/s41021-023-00267-4)
- 52. Rahal Z, Sinjab A, Wistuba II, Kadara H (2022) Game of clones: battles in the field of carcinogenesis. Pharmacol Ther 237:108251. <https://doi.org/10.1016/j.pharmthera.2022.108251>
- 53. Kurogi S, Hijiya N, Hidano S et al (2021) Downregulation of ZNF395 drives progression of pancreatic ductal adenocarcinoma through enhancement of growth potential. Pathobiology 88(5):374–382. <https://doi.org/10.1159/000514593>
- 54. Jordanovski D, Herwartz C, Pawlowski A, Taute S, Frommolt P, Steger G (2013) The hypoxia-inducible transcription factor ZNF395 is controlled by IkB kinase-signaling and activates genes involved in the innate immune response and cancer. PLoS ONE 8(9):e74911. <https://doi.org/10.1371/journal.pone.0074911>
- 55. Pang F, Zha R, Zhao Y et al (2014) MiR-525-3p enhances the migration and invasion of liver cancer cells by downregulating ZNF395. PLoS ONE 9(3):e90867. [https://doi.org/10.1371/jour](https://doi.org/10.1371/journal.pone.0090867)[nal.pone.0090867](https://doi.org/10.1371/journal.pone.0090867)
- 56. Cai Y, Crowther J, Pastor T et al (2016) Loss of chromosome 8p governs Tumor Progression and Drug Response by altering lipid metabolism. Cancer Cell 29(5):751–766. [https://doi.](https://doi.org/10.1016/j.ccell.2016.04.003) [org/10.1016/j.ccell.2016.04.003](https://doi.org/10.1016/j.ccell.2016.04.003)
- 57. Boeckle S, Pfister H, Steger G (2002) A new cellular factor recognizes E2 binding sites of papillomaviruses which mediate transcriptional repression by E2. Virology 293(1):103-117. [https://](https://doi.org/10.1006/viro.2001.1231) doi.org/10.1006/viro.2001.1231
- 58. Sichtig N, Korfer N, Steger G (2007) Papillomavirus binding factor binds to SAP30 and represses transcription via recruitment of the HDAC1 co-repressor complex. Arch Biochem Biophys 467(1):67–75. <https://doi.org/10.1016/j.abb.2007.08.015>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.